There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Guoxiang Xie |
| Institution: | University of Hawaii Cancer Center |
| Department: | Metabolomics Shared Resource |
| Country: | |
| Proposed Analysis: | The University of Hawaii Cancer Center's Metabolomics Shared Resource Laboratory, PI is Dr. Wei Jia, has metabolically profiled serum samples from the Alzheimer's Disease Metabolomics Consortium (ADMC) covering ADNI 1/G0/2 longitudinal samples. We aimed to: (1) Use longitudinal blood samples in the ADNl-1, -GO, -2 cohorts at baseline and within 3 year follow-up time points to examine the temporal relationships between changes in the metabolome and changes in indices of disease progression, global and domain-specific cognitive measures, cerebrospinal fluid (CSF) AD biomarkers, and structural and functional neuroimaging measures; (2) Create an integrated molecular Atlas for AD that connects genotypes and metabotypes in an effort to define common biochemical pathways impacted in AD and its progression. Using data generated from ADNI and other cohorts within AMP-AD, we will further define associations between genetic variants implicated in AD, metabolites, AD disease phenotypes and metabolic switches during disease progression. |
| Additional Investigators | |
| Investigator's Name: | Wei Jia |
| Proposed Analysis: | The University of Hawaii Cancer Center's Metabolomics Shared Resource Laboratory, PI is Dr. Wei Jia, has metabolically profiled serum samples from the Alzheimer's Disease Metabolomics Consortium (ADMC) covering ADNI 1/G0/2 longitudinal samples. We aimed to: (1) Use longitudinal blood samples in the ADNl-1, -GO, -2 cohorts at baseline and within 3 year follow-up time points to examine the temporal relationships between changes in the metabolome and changes in indices of disease progression, global and domain-specific cognitive measures, cerebrospinal fluid (CSF) AD biomarkers, and structural and functional neuroimaging measures; (2) Create an integrated molecular Atlas for AD that connects genotypes and metabotypes in an effort to define common biochemical pathways impacted in AD and its progression. Using data generated from ADNI and other cohorts within AMP-AD, we will further define associations between genetic variants implicated in AD, metabolites, AD disease phenotypes and metabolic switches during disease progression. |
| Investigator's Name: | Huizhen Zhang |
| Proposed Analysis: | ADNI metabolomics data analysis |
